What are HIV-1 vaccine drugs?

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

HIV-1 vaccine drugs are pharmacologic agents that share a common mechanism (typically targeting gp120 (HIV-1 envelope glycoprotein)). 0 are currently marketed, with 1 more in clinical development.

HIV-1 vaccine

0 marketed 1 in Phase 3

This page covers all HIV-1 vaccine drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting gp120 (HIV-1 envelope glycoprotein).

Targets

gp120 (HIV-1 envelope glycoprotein)

Phase 3 pipeline (1)

MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 · National Institute of Allergy and Infectious Diseases (NIAID) · Immunology / Infectious Disease
MN rgp120/HIV-1 and GNE8 rgp120/HIV-1 are recombinant gp120 envelope protein vaccines designed to elicit immune responses against HIV-1 by presenting the viral surface antigen.

Patent intelligence

hiv 1 vaccine patent landscape — aggregated cliff calendar, attackable patents, originator estates